Abigail Walker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Abigail Walker has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Pavol Surda
ENT department Guy's and St Thomas' NHS Foundation Trust London UK
5 shared publications - Carl Philpott
Department of Otolaryngology James Paget University Hospital NHS Foundation Trust Great Yarmouth UK
3 shared publications Claire Hopkins
Department of Otolaryngology, Guy’s and St Thomas’ NHS Foundation Trust
3 shared publications- Benjamin Stew
University Hospital Wales Cardiff UK
2 shared publications - Claire Hopkins
Department of Ear, Nose, and Throat, Guy's and St Thomas' Hospitals, London, United Kingdom
2 shared publications Iain Hathorn
University of Edinburgh Edinburgh UK
2 shared publications
Latest Publications
- 23 August 2025
- Published by Wiley in Clinical Otolaryngology
- Vol. 51 (1) , 159-163
A Prospective Pilot Study of the Efficacy of Oral Propranolol in Reduction of the Frequency and Severity of Epistaxis in Hereditary Haemorrhagic Telangiectasia
- 23 August 2025
- Published by Wiley in Clinical Otolaryngology
- Vol. 51 (1) , 159-163
A Prospective Pilot Study of the Efficacy of Oral Propranolol in Reduction of the Frequency and Severity of Epistaxis in Hereditary Haemorrhagic Telangiectasia
- Open Access
- 27 August 2024
- Published by Wiley
A prospective study of the efficacy of oral propranolol in reduction of the frequency and severity of epistaxis in Hereditary Haemorrhagic Telangiectasia
1) This pilot trial demonstrated utility of oral propranolol in management of epistaxis in HHT 2) Propranolol was effective in reducing the severity and frequency of nosebleeds in HHT, as measured by the epistaxis severity scale, and this improvement is mirrored by an improvement in global quality of life 3) Adverse effects were experienced by a minority of patients, with the most significant event being pitting oedema 4) Following cessation of treatment, patients demonstrated a trend of regression with worsening of epistaxis scores 5) Further investigation is justified by its favourable effects, wide availability, and minimal side effect profile
- 27 August 2024
- Published by Wiley
Open AccessA prospective study of the efficacy of oral propranolol in reduction of the frequency and severity of epistaxis in Hereditary Haemorrhagic Telangiectasia
1) This pilot trial demonstrated utility of oral propranolol in management of epistaxis in HHT 2) Propranolol was effective in reducing the severity and frequency of nosebleeds in HHT, as measured by the epistaxis severity scale, and this improvement is mirrored by an improvement in global quality of life 3) Adverse effects were experienced by a minority of patients, with the most significant event being pitting oedema 4) Following cessation of treatment, patients demonstrated a trend of regression with worsening of epistaxis scores 5) Further investigation is justified by its favourable effects, wide availability, and minimal side effect profile
- 6 June 2024
- Published by Springer Nature
- p. 411-430
Endoscopic Resection of Nasal and Paranasal Sinus Neoplasms
- 6 June 2024
- Published by Springer Nature
- p. 411-430
Endoscopic Resection of Nasal and Paranasal Sinus Neoplasms
- Open Access
- 20 July 2023
- Published by BMJ in BMJ Medicine
- Vol. 2 (1) , e000382
Post-viral olfactory loss and parosmia
The emergence of SARS-CoV-2 has brought olfactory dysfunction to the forefront of public awareness, because up to half of infected individuals could develop olfactory dysfunction. Loss of smell—which can be partial or total—in itself is debilitating, but the distortion of sense of smell (parosmia) that can occur as a consequence of a viral upper respiratory tract infection (either alongside a reduction in sense of smell or as a solo symptom) can be very distressing for patients. Incidence of olfactory loss after SARS-CoV-2 infection has been estimated by meta-analysis to be around 50%, with more than one in three who will subsequently report parosmia. While early loss of sense of smell is thought to be due to infection of the supporting cells of the olfactory epithelium, the underlying mechanisms of persistant loss and parosmia remain less clear. Depletion of olfactory sensory neurones, chronic inflammatory infiltrates, and downregulation of receptor expression are thought to contribute. There are few effective therapeutic options, so support and olfactory training are essential. Further research is required before strong recommendations can be made to support treatment with steroids, supplements, or interventions applied topically or injected into the olfactory epithelium in terms of improving recovery of quantitative olfactory function. It is not yet known whether these treatments will also achieve comparable improvements in parosmia. This article aims to contextualise parosmia in the setting of post-viral olfactory dysfunction, explore some of the putative molecular mechanisms, and review some of the treatment options available.
- 20 July 2023
- Published by BMJ in BMJ Medicine
- Vol. 2 (1) , e000382
Open AccessPost-viral olfactory loss and parosmia
The emergence of SARS-CoV-2 has brought olfactory dysfunction to the forefront of public awareness, because up to half of infected individuals could develop olfactory dysfunction. Loss of smell—which can be partial or total—in itself is debilitating, but the distortion of sense of smell (parosmia) that can occur as a consequence of a viral upper respiratory tract infection (either alongside a reduction in sense of smell or as a solo symptom) can be very distressing for patients. Incidence of olfactory loss after SARS-CoV-2 infection has been estimated by meta-analysis to be around 50%, with more than one in three who will subsequently report parosmia. While early loss of sense of smell is thought to be due to infection of the supporting cells of the olfactory epithelium, the underlying mechanisms of persistant loss and parosmia remain less clear. Depletion of olfactory sensory neurones, chronic inflammatory infiltrates, and downregulation of receptor expression are thought to contribute. There are few effective therapeutic options, so support and olfactory training are essential. Further research is required before strong recommendations can be made to support treatment with steroids, supplements, or interventions applied topically or injected into the olfactory epithelium in terms of improving recovery of quantitative olfactory function. It is not yet known whether these treatments will also achieve comparable improvements in parosmia. This article aims to contextualise parosmia in the setting of post-viral olfactory dysfunction, explore some of the putative molecular mechanisms, and review some of the treatment options available.
- Open Access
- 5 August 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (31) , e29979
Immunotherapy as a treatment modality for mucosal melanoma of the head and neck: A systematic review
Introduction: Mucosal melanoma (MM) is a rare disease, accounting for approximately 1.4% of all melanomas and only 0.03% of all new cancer diagnoses. Traditionally, it has been associated with a poor prognosis, with an overall 5-year survival rate of <25%. Progress in treatment has been hindered by its rarity and lack of evidence. However, studies on the treatment of subcutaneous melanoma with immunotherapy have demonstrated significant improvement in survival rates and have become a core part of oncological strategies. This paper discusses the revision of the evidence for the use of immunotherapy in the head and neck. Methods: This systematic review was conducted on January 19, 2019. The Medline and Embase databases were searched. In total, 509 articles were collated and screened. Inclusion criteria for the study included treatment-naive cohorts, cohorts with recurrent disease, primary outcomes with overall survival and disease-free survival at 5 years and at the longest follow-up, and studies of adults with MM in whom immunotherapy was reported as a treatment strategy. The exclusion criteria included duplicate papers, anatomical sites other than the head and neck, case reports, and those not published in English. Results: Fifty-two papers out of the 509 collated papers met the inclusion criteria. The results are shown as a comparison of yearly survival rates following different treatment modalities (immunotherapy vs nonimmunotherapy) at 2, 3, and 5 years. It was found that, with immunotherapy, survival rates at all intervals were higher than those without immunotherapy. Discussion: Immunotherapy outcomes in small studies have shown good data for increasing survival rates at yearly intervals in MM of the head and neck. Larger clinical trials are needed to accurately distinguish the efficacy and survival outcomes of immunotherapy when compared with treatment modalities, excluding immunotherapy. However, the ability to perform larger trials is limited by the rarity of MM of the head and neck.
- 5 August 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (31) , e29979
Open AccessImmunotherapy as a treatment modality for mucosal melanoma of the head and neck: A systematic review
Introduction: Mucosal melanoma (MM) is a rare disease, accounting for approximately 1.4% of all melanomas and only 0.03% of all new cancer diagnoses. Traditionally, it has been associated with a poor prognosis, with an overall 5-year survival rate of <25%. Progress in treatment has been hindered by its rarity and lack of evidence. However, studies on the treatment of subcutaneous melanoma with immunotherapy have demonstrated significant improvement in survival rates and have become a core part of oncological strategies. This paper discusses the revision of the evidence for the use of immunotherapy in the head and neck. Methods: This systematic review was conducted on January 19, 2019. The Medline and Embase databases were searched. In total, 509 articles were collated and screened. Inclusion criteria for the study included treatment-naive cohorts, cohorts with recurrent disease, primary outcomes with overall survival and disease-free survival at 5 years and at the longest follow-up, and studies of adults with MM in whom immunotherapy was reported as a treatment strategy. The exclusion criteria included duplicate papers, anatomical sites other than the head and neck, case reports, and those not published in English. Results: Fifty-two papers out of the 509 collated papers met the inclusion criteria. The results are shown as a comparison of yearly survival rates following different treatment modalities (immunotherapy vs nonimmunotherapy) at 2, 3, and 5 years. It was found that, with immunotherapy, survival rates at all intervals were higher than those without immunotherapy. Discussion: Immunotherapy outcomes in small studies have shown good data for increasing survival rates at yearly intervals in MM of the head and neck. Larger clinical trials are needed to accurately distinguish the efficacy and survival outcomes of immunotherapy when compared with treatment modalities, excluding immunotherapy. However, the ability to perform larger trials is limited by the rarity of MM of the head and neck.
- 5 April 2021
- Published by Wiley in Clinical Otolaryngology
- Vol. 46 (5) , 1037-1043
British Rhinological Society Consensus Guidance on the use of biological therapies for chronic rhinosinusitis with nasal polyps
Objectives: We set out to create Consensus Guidelines, based on current evidence and relative risks of adverse effects and the costs of different treatments, which reflect the views of the British Rhinological Society (BRS) Council on where the use of biologics should be positioned within treatment pathways for CRSwNP, specifically in the setting of the National Health Service (NHS).Design: An expert panel of 16 members was assembled. A review of the literature and evidence synthesis was undertaken and circulated to the panel. We used the RAND/UCLA methodology with a multi‐step process to make recommendations on the use of biologics.Setting: N/A.Participants: N/A.Results: Recommendations were made, based on underlying disease severity, prior treatments and co‐morbidities. A group of patients for whom biologics were considered an appropriate treatment option for CRSwNP was defined.Conclusions: Although biologics are not currently available for the treatment of CRSwNP, the BRS Council have defined a group of patients who have higher rates of “failure” with current treatment pathways, higher resource use and are more likely to suffer with uncontrolled symptoms. We would urge NICE to consider approval of biologics for such indications without applying further restrictions on use.
- 5 April 2021
- Published by Wiley in Clinical Otolaryngology
- Vol. 46 (5) , 1037-1043
British Rhinological Society Consensus Guidance on the use of biological therapies for chronic rhinosinusitis with nasal polyps
Objectives: We set out to create Consensus Guidelines, based on current evidence and relative risks of adverse effects and the costs of different treatments, which reflect the views of the British Rhinological Society (BRS) Council on where the use of biologics should be positioned within treatment pathways for CRSwNP, specifically in the setting of the National Health Service (NHS).Design: An expert panel of 16 members was assembled. A review of the literature and evidence synthesis was undertaken and circulated to the panel. We used the RAND/UCLA methodology with a multi‐step process to make recommendations on the use of biologics.Setting: N/A.Participants: N/A.Results: Recommendations were made, based on underlying disease severity, prior treatments and co‐morbidities. A group of patients for whom biologics were considered an appropriate treatment option for CRSwNP was defined.Conclusions: Although biologics are not currently available for the treatment of CRSwNP, the BRS Council have defined a group of patients who have higher rates of “failure” with current treatment pathways, higher resource use and are more likely to suffer with uncontrolled symptoms. We would urge NICE to consider approval of biologics for such indications without applying further restrictions on use.
- 21 July 2020
- Published by Wiley in Clinical Otolaryngology
- Vol. 45 (6) , 862-869
Defining appropriateness criteria for endoscopic sinus surgery in the management of adult dental implant patients with incidental maxillary sinus findings on conebeam computed tomography
Objectives: Conebeam computed tomography (CBCT) imaging is commonly requested by dental implant surgeons, preoperatively, for patients being considered for dental implants. Incidental maxillary sinus findings often result in otolaryngology (ENT) referral for further assessment.CBCT findings include transient and benign mucosal changes that may not require any intervention and therefore unnecessarily delay implant surgery.We aim to define appropriateness criteria for ESS in the management of adult dental implant patients with incidental maxillary sinus findings on CBCT and provide guidance to both dental implant and ENT surgeons.Design: The RAND/UCLA appropriateness methodology was used to develop and define the appropriateness criteria.Setting: A virtual panel of 13 international experts in ESS.Participants: The expert panel completed two rounds of a modified Delphi ranking process for nine clinical scenarios, considering various factors affecting decision‐making processes.Main outcome measures: To define appropriateness criteria for ESS in adult dental implant patients who have incidental maxillary sinus findings on CBCT.Results: Patients with clinical symptoms and endoscopic findings of chronic rhinosinusitis together with an obstructed ostiomeatal complex (OMC) and concentric mucosal thickening of the ipsilateral maxillary sinus or pansinusitis were deemed appropriate candidates for ESS prior to their dental implant. ESS was not appropriate in asymptomatic patients with a patent OMC and mucosal thickening isolated to floor of the ipsilateral maxillary sinus.For uncertain scenarios, further discussion between dental implant and ENT surgeon should be considered.Conclusions: This study has developed and reported a list of appropriateness criteria to offer ESS in adult dental implant patients with incidental maxillary sinus findings on CBCT.
- 21 July 2020
- Published by Wiley in Clinical Otolaryngology
- Vol. 45 (6) , 862-869
Defining appropriateness criteria for endoscopic sinus surgery in the management of adult dental implant patients with incidental maxillary sinus findings on conebeam computed tomography
Objectives: Conebeam computed tomography (CBCT) imaging is commonly requested by dental implant surgeons, preoperatively, for patients being considered for dental implants. Incidental maxillary sinus findings often result in otolaryngology (ENT) referral for further assessment.CBCT findings include transient and benign mucosal changes that may not require any intervention and therefore unnecessarily delay implant surgery.We aim to define appropriateness criteria for ESS in the management of adult dental implant patients with incidental maxillary sinus findings on CBCT and provide guidance to both dental implant and ENT surgeons.Design: The RAND/UCLA appropriateness methodology was used to develop and define the appropriateness criteria.Setting: A virtual panel of 13 international experts in ESS.Participants: The expert panel completed two rounds of a modified Delphi ranking process for nine clinical scenarios, considering various factors affecting decision‐making processes.Main outcome measures: To define appropriateness criteria for ESS in adult dental implant patients who have incidental maxillary sinus findings on CBCT.Results: Patients with clinical symptoms and endoscopic findings of chronic rhinosinusitis together with an obstructed ostiomeatal complex (OMC) and concentric mucosal thickening of the ipsilateral maxillary sinus or pansinusitis were deemed appropriate candidates for ESS prior to their dental implant. ESS was not appropriate in asymptomatic patients with a patent OMC and mucosal thickening isolated to floor of the ipsilateral maxillary sinus.For uncertain scenarios, further discussion between dental implant and ENT surgeon should be considered.Conclusions: This study has developed and reported a list of appropriateness criteria to offer ESS in adult dental implant patients with incidental maxillary sinus findings on CBCT.
- Open Access
- 8 July 2020
- Published by SAGE Publications in JRSM Open
- Vol. 11 (7)
Royal Society of Medicine Surgical Innovation Day Adrian Tanner Prize Winner 2019: Multidisciplinary care and surgical innovation for the benefit of the patient with head and neck cancer of unknown primary
Head and neck carcinoma of unknown primary accounts for approximately 1–5% of all head and neck cancers and presents a genuine diagnostic and therapeutic dilemma. Despite advanced investigations, the primary tumour location remains unknown in up to 40% of these cases. Transoral robotic surgery presents a viable diagnostic and therapeutic option in these patients. This surgical innovation alongside advances in the understanding of head and neck cancer biology means that a multidisciplinary approach in the management of these complex patients is of utmost importance to ensure optimal therapeutic outcomes.
- 8 July 2020
- Published by SAGE Publications in JRSM Open
- Vol. 11 (7)
Open AccessRoyal Society of Medicine Surgical Innovation Day Adrian Tanner Prize Winner 2019: Multidisciplinary care and surgical innovation for the benefit of the patient with head and neck cancer of unknown primary
Head and neck carcinoma of unknown primary accounts for approximately 1–5% of all head and neck cancers and presents a genuine diagnostic and therapeutic dilemma. Despite advanced investigations, the primary tumour location remains unknown in up to 40% of these cases. Transoral robotic surgery presents a viable diagnostic and therapeutic option in these patients. This surgical innovation alongside advances in the understanding of head and neck cancer biology means that a multidisciplinary approach in the management of these complex patients is of utmost importance to ensure optimal therapeutic outcomes.
- Open Access
- 26 April 2020
- Published by Wiley in Clinical Otolaryngology
- Vol. 45 (4) , 649-651
A framework for open tracheostomy in COVID‐19 patients
- 26 April 2020
- Published by Wiley in Clinical Otolaryngology
- Vol. 45 (4) , 649-651
Open AccessA framework for open tracheostomy in COVID‐19 patients